LitAlert ~~ GeneLit.com

    • Rare presentations can suggest more than one rare condition: Striking personal and family cancer history in a patient with both CDKN2A and BRCA1 pathogenic variants.
    • Trupiano N, Koeppe E, Jacobs MF, Else T, Cha KB.
    • JAAD Case Rep. 2022 Nov 7 [eCollection 2023 Jan];31:42-45. doi: 10.1016/j.jdcr.2022.10.034.

    • Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report.
    • Bian Y, Guan P, Li D, Tan L, Pang H, Wen Q, Chen P, Zhang Z.
    • Front Oncol. 2022 Dec 15;12:1071383. doi: 10.3389/fonc.2022.1071383.

    • FDA Delays PDUFA Hearing for Olaparib/Abiraterone Combo in mCRPC.
    • Harris J.
    • OncLive. 2022 Dec 15.

    Related:

    •• Identifier: NCT03732820: Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer. (ClinicalTrials.gov . Accessed 2022 Dec 15.)

    • Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients.
    • Gurioli G, Tedaldi G, Farolfi A, Petracci E, Casanova C, Comerci G, Danesi R, Arcangeli V, Ravegnani M, Calistri D, Zampiga V, Cangini I, Fonzi E, Virga A, Tassinari D, Rosati M, Ulivi P, De Giorgi U.
    • Int J Mol Sci. 2022 Dec 13;23(24):15789. doi: 10.3390/ijms232415789.

    • Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer.
    • Li C, Ye W, Zhou W, Ye Z, Yang W, Cheng Z.
    • Front Oncol. 2022 Dec 12;12:1010158. doi: 10.3389/fonc.2022.1010158.

    • Molecular profiling of male breast cancer by multigene panel testing: implications for precision oncology.
    • Valentini V, Silvestri V, Bucalo A, Conti G, Karimi M, Di Francesco L, Pomati G, Mezi S, Cerbelli B, Pignataro MG, Nicolussi A, Coppa A, D'Amati G, Giannini G, Ottini L.
    • Front Oncol. 2022 Dec 12;12:1092201. doi: 10.3389/fonc.2022.1092201.

    • SOLO1: 7-Year Follow-up Highlights the Value of Maintenance Olaparib.
    • Markman M.
    • Medscape Oncology. Perspective. 2022 Dec 12.

    Related:

    •• Original research:

    Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.

    • Myriad Genetics Generates More Data on its PRS's Ability to Identify Who Will Develop Breast Cancer.
    • Ray F.
    • Precision Oncology News. 2022 Dec 12.

    • Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients-a systematic review and meta-analysis.
    • Fazekas T, Széles ÁD, Teutsch B, Csizmarik A, Vékony B, Váradi A, Kói T, Lang Z, Ács N, Kopa Z, Hegyi P, Hadaschik B, Grünwald V, Nyirády P, Szarvas T.
    • Prostate Cancer Prostatic Dis. 2022 Dec 12. doi: 10.1038/s41391-022-00626-2. Epub ahead of print.